Top

Current Heart Failure Reports

Published in:

01-12-2019 | Kidney Injury | Biomarkers of Heart Failure (WH Tang & J Grodin, Section Editors)

Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?

Authors: Alexander S. Manguba Jr, Xavier Vela Parada, Steven G. Coca, Anuradha Lala

Published in: Current Heart Failure Reports | Issue 6/2019

Abstract

Purpose of Review

This review discusses evidence that has accumulated over the years on the diagnostic and prognostic utility of biomarkers of kidney injury in the setting of acute decompensated heart failure.

Recent Findings

Despite numerous studies evaluating several different biomarkers both in the serum and urine, the current body of evidence does not support routine use of any of these biomarkers for the purposes of diagnosis of acute kidney injury or for prognosis after hospitalization for acute decompensated heart failure. All studies are observational in nature and, as such, are likely limited by numerous confounders, the most important of which is modification of decongestive therapy in response to worsening renal function. More recent evidence suggests that worsening renal function or kidney injury does not always portend poor outcomes after hospitalization for heart failure.

Summary

There is currently no conclusive evidence to recommend the routine use of biomarkers of kidney injury in acute decompensated heart failure.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. https://doi.org/10.1161/CIR.0b013e31820a55f5.CrossRefPubMed

Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–69. https://doi.org/10.1093/eurheartj/eht386.CrossRefPubMed

Section 2: AKI Definition. Kidney Int Suppl (2011). 2012;2(1):19–36. https://doi.org/10.1038/kisup.2011.32.

Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e78. https://doi.org/10.1161/CIR.0000000000000664.CrossRefPubMed

Damman K, Tang WH, Testani JM, McMurray JJ. Terminology and definition of changes renal function in heart failure. Eur Heart J. 2014;35(48):3413–6. https://doi.org/10.1093/eurheartj/ehu320.CrossRefPubMedPubMedCentral

Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Franci B, et al. Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure. Am J Cardiol. 2015;116(1):104–11. https://doi.org/10.1016/j.amjcard.2015.03.043.CrossRefPubMed

Breidthardt T, Sabti Z, Ziller R, Rassouli F, Twerenbold R, Kozhuharov N, et al. Diagnostic and prognostic value of cystatin C in acute heart failure. Clin Biochem. 2017;50(18):1007–13. https://doi.org/10.1016/j.clinbiochem.2017.07.016.CrossRefPubMed

Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, Fukui A, et al. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail. 2005;11(8):595–601. https://doi.org/10.1016/j.cardfail.2005.06.001.CrossRefPubMed

Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841–7. https://doi.org/10.1093/eurheartj/ehl507.CrossRefPubMed

10.

Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, Pastor P, Garrido IP, Pastor-Perez FJ, et al. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol. 2009;103(12):1753–9. https://doi.org/10.1016/j.amjcard.2009.02.029.CrossRefPubMed

11.

Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, et al. Cystatin C in acute heart failure without advanced renal impairment. Am J Med. 2009;122(6):566–73. https://doi.org/10.1016/j.amjmed.2008.10.042.CrossRefPubMed

12.

Kim TH, Kim H, Kim IC. The potential of cystatin-C to evaluate the prognosis of acute heart failure: A comparative study. Acute Card Care. 2015;17(4):72–6. https://doi.org/10.1080/17482941.2016.1203440.CrossRefPubMed

13.

Rafouli-Stergiou P, Parissis J, Farmakis D, Bistola V, Nikolaou M, Vasiliadis K, et al. Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. Int J Cardiol. 2015;182:74–6. https://doi.org/10.1016/j.ijcard.2014.12.135.CrossRefPubMed

14.

Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, et al. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC Heart Fail. 2015;3(1):40–9. https://doi.org/10.1016/j.jchf.2014.06.014.CrossRefPubMed

15.

Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017;19(8):1001–10. https://doi.org/10.1002/ejhf.749.CrossRefPubMed

16.

Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A, et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail. 2016;18(12):1491–8. https://doi.org/10.1002/ejhf.543.CrossRefPubMed

17.

Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, et al. Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI Heart Failure Network Clinical Trials. J Card Fail. 2018;24(7):428–38. https://doi.org/10.1016/j.cardfail.2018.02.002.CrossRefPubMedPubMedCentral

18.

Legrand M, De Berardinis B, Gaggin HK, Magrini L, Belcher A, Zancla B, et al. Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study. PLoS One. 2014;9(11):e112313. https://doi.org/10.1371/journal.pone.0112313.CrossRefPubMedPubMedCentral

19.

Sokolski M, Zymlinski R, Biegus J, Siwolowski P, Nawrocka-Millward S, Todd J, et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur J Heart Fail. 2017;19(6):760–7. https://doi.org/10.1002/ejhf.746.CrossRefPubMed

20.

Bonventre JV, Yang L. Kidney injury molecule-1. Curr Opin Crit Care. 2010;16(6):556–61. https://doi.org/10.1097/MCC.0b013e32834008d3.CrossRefPubMed

21.

Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014;25(10):2177–86. https://doi.org/10.1681/ASN.2013070758.CrossRefPubMedPubMedCentral

22.

Verbrugge FH, Dupont M, Shao Z, Shrestha K, Singh D, Finucan M, et al. Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure. J Card Fail. 2013;19(9):621–8. https://doi.org/10.1016/j.cardfail.2013.07.004.CrossRefPubMedPubMedCentral

23.

•• Ahmad T, Jackson K, Rao VS, WHW T, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137(19):2016–28. https://doi.org/10.1161/CIRCULATIONAHA.117.030112This study provides evidence that that worsening renal function in the setting of decongestive therapy for heart failure is not always associated with tubular injury, and that patients with an increase in tubular injury markers have paradoxically improved outcomes. CrossRefPubMedPubMedCentral

24.

Grodin JL, Perez AL, Wu Y, Hernandez AF, Butler J, Metra M, et al. Circulating kidney injury molecule-1 levels in acute heart failure: insights from the ASCEND-HF Trial (Acute study of clinical effectiveness of nesiritide in decompensated heart failure). JACC Heart Fail. 2015;3(10):777–85. https://doi.org/10.1016/j.jchf.2015.06.006.CrossRefPubMed

25.

Emmens JE, Ter Maaten JM, Matsue Y, Metra M, O'Connor CM, Ponikowski P, et al. Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. Eur J Heart Fail. 2016;18(6):641–9. https://doi.org/10.1002/ejhf.426.CrossRefPubMed

26.

Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15(12):3073–82. https://doi.org/10.1097/01.ASN.0000145013.44578.45.CrossRefPubMed

27.

Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury--where do we stand today? Nephrol Dial Transplant. 2011;26(3):762–4. https://doi.org/10.1093/ndt/gfr006.CrossRefPubMed

28.

Dupont M, Shrestha K, Singh D, Awad A, Kovach C, Scarcipino M, et al. Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail. 2012;14(6):597–604. https://doi.org/10.1093/eurjhf/hfs039.CrossRefPubMedPubMedCentral

29.

Murray PT, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, et al. Utility of urine neutrophil gelatinase-associated lipocalin for worsening renal function during hospitalization for acute heart failure: primary findings for urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic heart faIlure Study (AKINESIS). J Card Fail. 2019. https://doi.org/10.1016/j.cardfail.2019.05.009.CrossRefPubMed

30.

Nakada Y, Kawakami R, Matsui M, Ueda T, Nakano T, Takitsume A, et al. Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J Am Heart Assoc. 2017;6(5). https://doi.org/10.1161/JAHA.116.004582.

31.

Shirakabe A, Hata N, Kobayashi N, Okazaki H, Shinada T, Tomita K, et al. Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J. 2015;79(1):119–28. https://doi.org/10.1253/circj.CJ-14-0653.CrossRefPubMed

32.

Shrestha K, Shao Z, Singh D, Dupont M, Tang WH. Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol. 2012;110(9):1329–35. https://doi.org/10.1016/j.amjcard.2012.06.035.CrossRefPubMedPubMedCentral

33.

Soyler C, Tanriover MD, Ascioglu S, Aksu NM, Arici M. Urine neutrophil gelatinase-associated lipocalin levels predict acute kidney injury in acute decompensated heart failure patients. Ren Fail. 2015;37(5):772–6. https://doi.org/10.3109/0886022X.2015.1033324.CrossRefPubMed

34.

Yang X, Chen C, Tian J, Zha Y, Xiong Y, Sun Z, et al. Urinary angiotensinogen level predicts AKI in acute decompensated heart failure: a prospective, two-stage study. J Am Soc Nephrol. 2015;26(8):2032–41. https://doi.org/10.1681/ASN.2014040408.CrossRefPubMedPubMedCentral

35.

Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16(1):49–54. https://doi.org/10.1016/j.cardfail.2009.07.003.CrossRefPubMed

36.

Alvelos M, Pimentel R, Pinho E, Gomes A, Lourenco P, Teles MJ, et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol. 2011;6(3):476–81. https://doi.org/10.2215/CJN.06140710.CrossRefPubMedPubMedCentral

37.

Macdonald S, Arendts G, Nagree Y, Xu XF. Neutrophil gelatinase-associated lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord. 2012;12:8. https://doi.org/10.1186/1471-2261-12-8.CrossRefPubMedPubMedCentral

38.

Maisel AS, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, et al. Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations: the AKINESIS Study. J Am Coll Cardiol. 2016;68(13):1420–31. https://doi.org/10.1016/j.jacc.2016.06.055.CrossRefPubMed

39.

Damman K, Valente MAE, van Veldhuisen DJ, Cleland JGF, O’Connor CM, Metra M, et al. Plasma neutrophil gelatinase-associated lipocalin and predicting clinically relevant worsening renal function in acute heart failure. Int J Mol Sci. 2017;18(7). https://doi.org/10.3390/ijms18071470.CrossRefPubMedCentral

40.

Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13(8):846–51. https://doi.org/10.1093/eurjhf/hfr087.CrossRefPubMedPubMedCentral

41.

Alvelos M, Lourenco P, Dias C, Amorim M, Rema J, Leite AB, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2013;165(1):51–5. https://doi.org/10.1016/j.ijcard.2011.07.080.CrossRefPubMed

42.

van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, van Veldhuisen DJ, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail. 2014;7(1):35–42. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000242.CrossRefPubMed

43.

Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. Worsening renal failure in patients with acute heart failure: the importance of cardiac biomarkers. ESC Heart Fail. 2019;6(2):416–27. https://doi.org/10.1002/ehf2.12414.CrossRefPubMedPubMedCentral

44.

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87. https://doi.org/10.1124/pr.59.3.3.CrossRefPubMed

45.

Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61(2):579–85. https://doi.org/10.1046/j.1523-1755.2002.00155.x.CrossRefPubMedPubMedCentral

46.

Ba Aqeel SH, Sanchez A, Batlle D. Angiotensinogen as a biomarker of acute kidney injury. Clin Kidney J. 2017;10(6):759–68. https://doi.org/10.1093/ckj/sfx087.CrossRefPubMedPubMedCentral

47.

Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991;273(Pt 3):759–66. https://doi.org/10.1042/bj2730759.CrossRefPubMedPubMedCentral

48.

Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. Clinical usefulness of urinary liver fatty acid-binding protein excretion for predicting acute kidney injury during the first 7 days and the short-term prognosis in acute heart failure patients with non-chronic kidney disease. Cardiorenal Med. 2017;7(4):301–15. https://doi.org/10.1159/000477825.CrossRefPubMedPubMedCentral

49.

Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, et al. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of acute kidney injury in patients with acute decompensated heart failure. Cardiorenal Med. 2017;7(4):267–75. https://doi.org/10.1159/000476002.CrossRefPubMedPubMedCentral

50.

Okubo Y, Sairaku A, Morishima N, Ogi H, Matsumoto T, Kinoshita H, et al. Increased urinary liver-type fatty acid-binding protein level predicts worsening renal function in patients with acute heart failure. J Card Fail. 2018;24(8):520–4. https://doi.org/10.1016/j.cardfail.2018.07.003.CrossRefPubMed

51.

Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43(3):405–14.CrossRefPubMed

52.

Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16(10):3046–52. https://doi.org/10.1681/ASN.2005030236.CrossRefPubMed

53.

Neves FM, Meneses GC, Sousa NE, Menezes RR, Parahyba MC, Martins AM, et al. Syndecan-1 in acute decompensated heart failure--association with renal function and mortality. Circ J. 2015;79(7):1511–9. https://doi.org/10.1253/circj.CJ-14-1195.CrossRefPubMed

54.

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25. https://doi.org/10.1186/cc12503.CrossRefPubMedPubMedCentral

55.

Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One. 2014;9(3):e93460. https://doi.org/10.1371/journal.pone.0093460.CrossRefPubMedPubMedCentral

56.

Schanz M, Shi J, Wasser C, Alscher MD, Kimmel M. Urinary [TIMP-2] x [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin Cardiol. 2017;40(7):485–91. https://doi.org/10.1002/clc.22683.CrossRefPubMedPubMedCentral

57.

Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal. 2001;24(5-6):835–42. https://doi.org/10.1016/s0731-7085(00)00550-1.CrossRefPubMed

58.

Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. https://doi.org/10.1155/2016/4647685.CrossRefPubMedPubMedCentral

59.

Kawai K, Kawashima S, Miyazaki T, Tajiri E, Mori M, Kitazaki K, et al. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients. J Cardiol. 2010;55(1):99–107. https://doi.org/10.1016/j.jjcc.2009.10.003.CrossRefPubMed

60.

Filler G, Kusserow C, Lopes L, Kobrzynski M. Beta-trace protein as a marker of GFR--history, indications, and future research. Clin Biochem. 2014;47(13-14):1188–94. https://doi.org/10.1016/j.clinbiochem.2014.04.027.CrossRefPubMed

61.

Manzano-Fernández S, Januzzi JL, Boronat-Garcia M, Bonaque-González JC, Truong QA, Pastor-Pérez FJ, et al. β-Trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol. 2011;57(7):849–58. https://doi.org/10.1016/j.jacc.2010.08.644.CrossRefPubMed

62.

Hoffmann D, Bijol V, Krishnamoorthy A, Gonzalez VR, Frendl G, Zhang Q, et al. Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am J Pathol. 2012;181(3):818–28. https://doi.org/10.1016/j.ajpath.2012.06.004.CrossRefPubMedPubMedCentral

63.

Koyama S, Sato Y, Tanada Y, Fujiwara H, Takatsu Y. Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure. Circ Heart Fail. 2013;6(2):227–32. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000152.CrossRefPubMed

64.

Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol. 2009;104(3):389–92. https://doi.org/10.1016/j.amjcard.2009.03.059.CrossRefPubMed

65.

Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, Martinez-Marcos FJ, Camacho-Vazquez C, Ruiz-Frutos C, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail. 2011;17(1):31–8. https://doi.org/10.1016/j.cardfail.2010.07.248.CrossRefPubMed

66.

Carrasco-Sanchez FJ, Perez-Calvo JI, Morales-Rull JL, Galisteo-Almeda L, Paez-Rubio I, Baron-Franco B, et al. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels. J Cardiovasc Med (Hagerstown). 2014;15(2):115–21. https://doi.org/10.2459/JCM.0b013e3283654bab.CrossRef

67.

Flores-Blanco PJ, Manzano-Fernandez S, Perez-Calvo JI, Pastor-Perez FJ, Ruiz-Ruiz FJ, Carrasco-Sanchez FJ, et al. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure. Clin Cardiol. 2015;38(2):106–13. https://doi.org/10.1002/clc.22362.CrossRefPubMedPubMedCentral

68.

Inazumi H, Koyama S, Tanada Y, Fujiwara H, Takatsu Y, Sato Y. Prognostic significance of changes in cystatin C during treatment of acute cardiac decompensation. J Cardiol. 2016;67(1):98–103. https://doi.org/10.1016/j.jjcc.2015.04.014.CrossRefPubMed

69.

Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirila-Waris K, Sund R, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31(22):2791–8. https://doi.org/10.1093/eurheartj/ehq293.CrossRefPubMed

70.

Pérez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, Morales-Rull JL, Manzano-Fernández S, Galisteo-Almeda L, et al. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med. 2012;23(7):599–603. https://doi.org/10.1016/j.ejim.2012.06.002.CrossRefPubMed

71.

Ruan ZB, Zhu L, Yin YG, Chen GC. Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: insights into the cardiorenal syndrome. J Res Med Sci. 2014;19(5):404–9.PubMedPubMedCentral

72.

Selcuk H, Selcuk MT, Maden O, Balci KG, Balci MM, Tekeli S, et al. The impact of admission cystatin C levels on in-hospital and three-year mortality rates in acute decompensated heart failure. Cardiovasc J Afr. 2018;29(5):305–9. https://doi.org/10.5830/CVJA-2018-035.CrossRefPubMedPubMedCentral

73.

Breidthardt T, Socrates T, Drexler B, Noveanu M, Heinisch C, Arenja N, et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care. 2012;16(1):R2. https://doi.org/10.1186/cc10600.CrossRefPubMedPubMedCentral

74.

Chen C, Yang X, Lei Y, Zha Y, Liu H, Ma C, et al. Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome. Clin J Am Soc Nephrol. 2016;11(9):1536–44. https://doi.org/10.2215/CJN.00910116.CrossRefPubMedPubMedCentral

75.

Mortara A, Bonadies M, Mazzetti S, Fracchioni I, Delfino P, Chioffi M, et al. Neutrophil gelatinase-associated lipocalin predicts worsening of renal function in acute heart failure: methodological and clinical issues. J Cardiovasc Med (Hagerstown). 2013;14(9):629–34. https://doi.org/10.2459/JCM.0b013e3283629ca6.CrossRef

76.

Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol. 2012;23(1):13–21. https://doi.org/10.1681/ASN.2010111124.CrossRefPubMedPubMedCentral

77.

Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54–62. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413.CrossRefPubMed

78.

Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, et al. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC Heart Fail. 2015;3(10):751–61. https://doi.org/10.1016/j.jchf.2015.05.009.CrossRefPubMed

79.

Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, OF AE, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8(4):741–8. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001957.CrossRefPubMedPubMedCentral

80.••

Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, et al. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE Trial. J Card Fail. 2016;22(10):753–60. https://doi.org/10.1016/j.cardfail.2016.06.423This analysis of data from the Heart Failure Network DOSE trial found that an increase in creatinine was paradoxically associated with improved outcomes. CrossRefPubMedPubMedCentral

81.

Stolfo D, Stenner E, Merlo M, Porto AG, Moras C, Barbati G, et al. Prognostic impact of BNP variations in patients admitted for acute decompensated heart failure with in-hospital worsening renal function. Heart Lung Circ. 2017;26(3):226–34. https://doi.org/10.1016/j.hlc.2016.06.1205.CrossRefPubMed

82.

Davila C, Reyentovich A, Katz SD. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure. J Card Fail. 2011;17(12):1018–22. https://doi.org/10.1016/j.cardfail.2011.08.004.CrossRefPubMed

83.

Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol. 2013;62(6):516–24. https://doi.org/10.1016/j.jacc.2013.05.027.CrossRefPubMedPubMedCentral

84.

Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–72. https://doi.org/10.1161/CIRCULATIONAHA.109.933275.CrossRefPubMedPubMedCentral

85.

van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61(19):1973–81. https://doi.org/10.1016/j.jacc.2012.12.050.CrossRefPubMed

86.••

Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED, et al. Renal effects of intensive volume removal in heart failure patients with preexisting worsening renal function. Circ Heart Fail. 2019;12(6):e005552. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005552This study showed that aggressive diuresis in patients with preexisting worsening renal function does not always lead to further worsening of renal function, and that those who had increase in biomarkers of tubular injury tended to have better improvement in renal function. CrossRefPubMedPubMedCentral

87.

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533–43. https://doi.org/10.1001/jama.2013.282190.CrossRefPubMedPubMedCentral

88.

Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7. https://doi.org/10.1001/jama.287.12.1541.CrossRefPubMed

89.

O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. https://doi.org/10.1056/NEJMoa1100171.CrossRefPubMed

90.

Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011;57(19):1899–907. https://doi.org/10.1016/j.jacc.2010.11.057.CrossRefPubMed

Title: Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?
Authors: Alexander S. Manguba Jr
Xavier Vela Parada
Steven G. Coca
Anuradha Lala
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Kidney Injury
Acute Kidney Injury
Heart Failure
Acute Kidney Injury
Biomarkers
Published in: Current Heart Failure Reports / Issue 6/2019
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-019-00448-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2019

Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

The Approach to the Psychosocial Evaluation of Cardiac Transplant and Mechanical Circulatory Support Candidates

Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does “X” Really Mark the Spot?

Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure

Role of Palliative Care in the Outpatient Management of the Chronic Heart Failure Patient

Right Ventricular Strain to Assess Early Right Heart Failure in the Left Ventricular Assist Device Candidate

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page